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colonization of the bronchi, along with its immuno- 
logical consequences, is an incidental complication of 
pre-existing asthma. On the whole the first explanation 
would seem the more likely, but perhaps Professor 
Seaton’s impending publication will help to resolve 
that particular controversy. 
I. W. B. GRANT 
Nether Balchandy, 
By Pitlochry, 
Perthshire PHI6 SJT, U.K. 
13 May 1993 
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Dear Editor 
I read with some concern the article ‘Respiratory 
arrests in young asthmatics on salmeterol’ by C. E. 
Clark et al. in Respiratory Medicine (1993) 87: 
227-228. Whilst one accepts that case reports can 
communicate interesting clinical findings, this paper 
oversteps the boundary of observation and attempts to 
make the case for a causal link between respiratory 
arrests and the commencement of salmeterol 14 
weeks earlier. The authors’ case is not proven, and 
circumstantial. 
I wish to make the following observations: 
Case 1 was of considerable severity with so many 
treatment variables, that it is hard to see why one drug 
was selected as a cause rather than a variation in the 
severity of asthma. The authors do not indicate if this 
patient had circulating therapeutic levels of theo- 
phylline and do not objectively document the persist- 
ent early morning tightness. They do not indicate what 
drugs were used in the nebulizer, was it salbutamol, or 
salbutamol and ipratropium bromide? On the day of 
the respiratory arrest did this patient respond, poss- 
ibly, to a &-agonist by nebulizer. This needs clarifica- 
tion because if the patient received salbutamol at 
this time the case against salmeterol is somewhat 
weakened. 
In Case 2 the patient’s asthma was poorly controlled 
following commencement of work at a wood pulping 
mill. The authors should make it clear whether he has 
occupational asthma or not. Again it is hard to sustain 
an argument that 5Opg b.d. of a long acting agent at 
the &adrenoreceptor is the cause of the respiratory 
arrest when he was tolerating each day 1Omg of 
nebulized salbutamol. He was also on a small dose of 
inhaled corticosteroid for poorly controlled asthma 
and one wonders why the authors did not first convert 
to high dose inhaled steroids or oral steroid before 
introducing the salmeterol, an approach adopted by 
many of us when first using salmeterol, and which 
subsequently is recommended in both national and 
international guidelines. 
This young man (Case 3) had mild asthma but was 
probably was not adequately treated with 10 mg b.d. 
of sodium cromoglycate and terbutaline on a q.d.s. 
regimen. We are not told how frequently he had 
symptoms, apart from lack of exercise symptoms, 
despite regular sporting activity. The authors fail to 
justify the commencement of salmeterol. Again in his 
case there are variables which could be influencing the 
asthma other than the introduction of salmeterol 4 
weeks earlier. What was the time ofyear the tennis was 
being played, were they grass courts and had the grass 
been mown that day? 
Based on these cases the authors correctly say there 
is no proof that these events were precipitated by 
salmeterol, but comment ‘. . . lead us to conclude that 
such an association is possible . .‘. They use the death 
of a single further patient in their area as some sort 
of support, that excessive near deaths were due to 
salmeterol though statistically this is irrelevant and a 
highly circumstantial comment. 
From the date of submission of this paper and its 
acceptance, 9 months later, I would suspect the report 
reflects early experience with the use of salmeterol, 
which had only come into use approximately 14 
months earlier and did not appear in the then current 
national guidelines published in 1990. It would 
be a pity if this useful agent were to be labelled 
dangerous on the basis of the slim evidence presented 
in this paper. The authors comment on the Serevent 
Nationwide Surveillance study from which early infor- 
mation on over 2.5 000 patients suggests salmeterol is a 
safe drug. Clearly, one must be cautious in ascribing a 
causal relationship, either directly stated or implied, as 
in this paper, based on inconclusive evidence. 
D.J. SHALE 
Section of Respiratory Medicine, 
Department of Medicine, 
Llandough Hospital, Penarth, 
CardlfCF6 IXX, U.K. 
7 May 1993 
Reply to the letter from Professor Shale 
Professor Shale has correctly surmised that our re- 
port is based on some early experiences with salmeterol 
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although two of us (C.E.C. and J.A.S.) had also used it 
in pre-marketing trials. Our attention was focused on 
salmeterol by the occurrence of these three cases over a 
3-month period which suggested to us that the intro- 
duction of a new preparation could have been the 
common thread. We emphasize that we do not claim 
proof for any association. 
To address Professor Shale’s specific points: 
The first patient used salbutamol in her nebulizer to 
which she partially responded on the day of her arrest. 
We have documented her case as fully as possible. 
All of these arrests happened outside of hospital so 
acute investigations were not available. They all bear 
witness to their general practitioners’ competence in 
resuscitation. 
In Case 2 the asthma was not occupational, but 
dated from childhood as we have stated. The compara- 
tive dosages of salbutamol and salmeterol do not 
justify an argument against the latter, in fact it is 
interesting that although he was responding to large 
doses of salbutamol he was not helped by salmeterol, 
suggesting that perhaps our understanding of how 
these drugs act at the receptor is limited. Our report 
states that he was taking oral prednisolone, never less 
than 6 mg per day, before salmeterol was added which 
is in accordance with the guidelines. 
We have perhaps not made it clear that in Case 3 
salmeterol was started by the general practitioner. It 
seems in retrospect that his mild and apparently con- 
trolled asthma may not have warranted this. At the 
same time his cromoglycate was withdrawn, when it 
may in fact have been controlling his asthma. This case 
seems to us to be the most worrying and we welcome 
the inclusion of salmeterol in the newly published 
guidelines (1). The arrest occurred in March and we 
presume that he was not therefore exposed to freshly 
mown grass. 
Salmeterol has without doubt benefited asthmatics 
under our care and is a useful drug. We have clearly 
stated that we cannot prove an association and 
nowhere do we seek to justify our cases with our local 
asthma death which was only quoted to provide per- 
spective. Non fatal deteriorations would in any case 
outnumber asthma deaths. We do however continue to 
believe that salmeterol may not suit all moderate or 
severe asthmatics and we note with interest that the 
Serevent Nationwide Surveillance study has shown a 
non significant excess of deaths in asthmatics treated 
with salmeterol compared to salbutamol (0.07% vs. 
0.02%) (2) and further examination of these figures 
has led others to question safety in young asthmatics 
(3). It is reassuring to see that the new guidelines 
support our previously stated policy of only 
prescribing salmeterol in conjunction with at least 
inhaled steroids. The fact that our first two cases were 
in fact managed according to the as then unpublished 
guidelines, but failed to show clinical improvement, 
provides anecdotal evidence that problems can still 
arise despite following them. We believe this streng- 
thens our suggestion that cases should be monitored 
individually and that if a patient shows no benefit from 
salmeterol it should be withdrawn promptly. 
C.CLARK 
Department of Respiratory Medicine, 
Royal Devon & Exeter Hospital ( Wonford), 
Barrack Road, 
Exeter EX2 5D W, U.K. 
14 June 1993 
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